When can we expect results on whether rituximab will work for other types of vasculitis?

Studies have been performed that suggest that rituximab works well in cryoglobulinemic vasculitis particularly when associated with hepatitis C infection, and some of these studies are already published. Other types of vasculitis in which rituximab seems likely to work (polyarteritis nodosa, EGPA/Churg-Strauss) are more difficult to study due to their rarity. It seems unlikely that rituximab would be effective in giant cell arteritis or Takayasu’s arteritis, and therefore it may be a long time before studies are done in these diseases.

(Click the back button in your browser to go back to the FAQ page.)